AstraZeneca declines BTG option

AstraZeneca plc (LSE:AZN; NYSE:AZN) declined to exercise an option to license Type II diabetes candidate CM-3 from BTG plc (LSE:BGC). According to BTG, AstraZeneca made the decision after reviewing undisclosed Phase I data for the glucagon-like peptide-1 (GLP-1) analog. AstraZeneca gained the option in 2009 from Biocompatibles International plc, which BTG acquired in January (see BioCentury, Dec. 6, 2010). ...